Carregant...

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

INTRODUCTION: To determine the feasibility, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT) of pazopanib in combination with cisplatin. METHODS: Patients with advanced malignancies were included in a 3 + 3 dose-escalation phase I study. Pazopanib administration started 8 days before...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Ther
Autors principals: Diéras, Véronique, Bachelot, Thomas, Campone, Mario, Isambert, Nicolas, Joly, Florence, Le Tourneau, Christophe, Cassier, Philippe, Bompas, Emmanuelle, Fumoleau, Pierre, Noal, Sabine, Orsini, Christine, Jimenez, Marta, Imbs, Diane Charlotte, Chatelut, Etienne
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315079/
https://ncbi.nlm.nih.gov/pubmed/28261651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0027-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!